A modeling analysis of the effects of molecular size and binding affinity on tumor targeting

被引:438
作者
Schmidt, Michael M. [2 ]
Wittrup, K. Dane [1 ,2 ,3 ]
机构
[1] MIT, Dept Chem Engn, Cambridge, MA 02139 USA
[2] MIT, Dept Biol Engn, Cambridge, MA 02139 USA
[3] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA
关键词
AFFIBODY MOLECULE; VASCULAR-PERMEABILITY; PICOMOLAR AFFINITY; DRUG CARRIERS; SOLID TUMORS; ANTIBODY; MACROMOLECULES; PENETRATION; BIODISTRIBUTION; NANOPARTICLES;
D O I
10.1158/1535-7163.MCT-09-0195
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A diverse array of tumor targeting agents ranging in size from peptides to nanoparticles is currently under development for applications in cancer imaging and therapy. However, it remains largely unclear how size differences among these molecules influence their targeting properties. Here, we develop a simple, mechanistic model that can be used to understand and predict the complex interplay between molecular size, affinity, and tumor uptake. Empirical relationships between molecular radius and capillary permeability, interstitial diffusivity, available volume fraction, and plasma clearance were obtained using data in the literature. These relationships were incorporated into a compartmental model of tumor targeting using MATLAB to predict the magnitude, specificity, time dependence, and affinity dependence of tumor uptake for molecules across a broad size spectrum. In the typical size range for proteins, the model uncovers a complex trend in which intermediate-sized targeting agents NW, similar to 25 kDa) have the lowest tumor uptake, whereas higher tumor uptake levels are achieved by smaller and larger agents. Small peptides accumulate rapidly in the tumor but require high affinity to be retained, whereas larger proteins can achieve similar retention with >100-fold weaker binding. For molecules in the size range of liposomes, the model predicts that antigen targeting will not significantly increase tumor uptake relative to untargeted molecules. All model predictions are shown to be consistent with experimental observations from published targeting studies. The results and techniques have implications for drug development, imaging, and therapeutic dosing. [Mol Cancer Ther 2009;8(10):2861-71]
引用
收藏
页码:2861 / 2871
页数:11
相关论文
共 51 条
[41]  
THOMAS GD, 1989, CANCER RES, V49, P3290
[42]   Factors determining antibody distribution in tumors [J].
Thurber, Greg M. ;
Schmidt, Michael M. ;
Wittrup, K. Dane .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2008, 29 (02) :57-61
[43]   Theoretic criteria for antibody penetration into solid tumors and micrometastases [J].
Thurber, Greg M. ;
Zajic, Stefan C. ;
Wittrup, K. Dane .
JOURNAL OF NUCLEAR MEDICINE, 2007, 48 (06) :995-999
[44]   99mTc-maEEE-ZHER2:342, an affibody molecule-based tracer for the detection of HER2 expression in malignant tumors [J].
Tran, Thuy ;
Engfeldt, Torun ;
Orlova, Anna ;
Sandstroem, Mattias ;
Feldwisch, Joachim ;
Abrahmsen, Lars ;
Wennborg, Anders ;
Tolmachev, Vladimir ;
Karlstroem, Amelie Eriksson .
BIOCONJUGATE CHEMISTRY, 2007, 18 (06) :1956-1964
[45]   Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5 [J].
Tsai, SW ;
Sun, YY ;
Williams, LE ;
Raubitschek, AA ;
Wu, AM ;
Shively, JE .
BIOCONJUGATE CHEMISTRY, 2000, 11 (03) :327-334
[46]   [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma [J].
Wicki, Andreas ;
Wild, Damian ;
Storch, Daniel ;
Seemayer, Christian ;
Gotthardt, Martin ;
Behe, Martin ;
Kneifel, Stefan ;
Mihatsch, Michael J. ;
Reubi, Jean-Claude ;
Maecke, Helmut R. ;
Christofori, Gerhard .
CLINICAL CANCER RESEARCH, 2007, 13 (12) :3696-3705
[47]   Numerical selection of optimal tumor imaging agents with application to engineered antibodies [J].
Williams, LE ;
Wu, AM ;
Yazaki, PJ ;
Liu, A ;
Raubitschek, AA ;
Shively, JE ;
Wong, JYC .
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2001, 16 (01) :25-35
[48]   Tumor targeting of mono-, di-, and tetravalent Anti-p185HER-2 miniantibodies multimerized by self-associating peptides [J].
Willuda, J ;
Kubetzko, S ;
Waibel, R ;
Schubiger, PA ;
Zangemeister-Wittke, U ;
Plückthun, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (17) :14385-14392
[49]   THE FINE STRUCTURE OF THE RENAL GLOMERULUS OF THE MOUSE [J].
YAMADA, E .
JOURNAL OF BIOPHYSICAL AND BIOCHEMICAL CYTOLOGY, 1955, 1 (06) :551-&
[50]  
YUAN F, 1995, CANCER RES, V55, P3752